Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study.
Coronavirus disease 2019
Cytokine release syndrome
Tocilizumab
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
09
04
2020
revised:
21
05
2020
accepted:
21
05
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Patients with severe coronavirus disease 2019 (COVID-19) have elevated levels of acute phase reactants and inflammatory cytokines, including interleukin-6, indicative of cytokine release syndrome (CRS). The interleukin-6 receptor inhibitor tocilizumab is used for the treatment of chimeric antigen receptor T-cell therapy-induced CRS. Patients aged 18 years or older with laboratory-confirmed COVID-19 admitted to the Annunziata Hospital in Cosenza, Italy, through March 7, 2020, who received at least one dose of tocilizumab 162 mg subcutaneously for the treatment of COVID-19-related CRS in addition to standard care were included in this retrospective observational study. The primary observation was the incidence of grade 4 CRS after tocilizumab treatment. Chest computed tomography (CT) scans were evaluated to investigate lung manifestations. Twelve patients were included; all had fever, cough, and fatigue at presentation, and all had at least one comorbidity (hypertension, six patients; diabetes, five patients; chronic obstructive lung disease, four patients). Seven patients received high-flow nasal cannula oxygen therapy and five received non-invasive mechanical ventilation for lung complications of COVID-19. No incidence of grade 4 CRS was observed within 1 week of tocilizumab administration in all 12 patients (100%) and within 2 days of tocilizumab administration in 5 patients (42%). The predominant pattern on chest CT scans at presentation was ground-glass opacity, air bronchograms, smooth or irregular interlobular or septal thickening, and thickening of the adjacent pleura. Follow-up CT scans 7 to 10 days after tocilizumab treatment showed improvement of lung manifestations in all patients. No adverse events or new safety concerns attributable to tocilizumab were reported. Tocilizumab administered subcutaneously to patients with COVID-19 and CRS is a promising treatment for reduction in disease activity and improvement in lung function. The effect of tocilizumab should be confirmed in a randomised controlled trial.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with severe coronavirus disease 2019 (COVID-19) have elevated levels of acute phase reactants and inflammatory cytokines, including interleukin-6, indicative of cytokine release syndrome (CRS). The interleukin-6 receptor inhibitor tocilizumab is used for the treatment of chimeric antigen receptor T-cell therapy-induced CRS.
METHODS
METHODS
Patients aged 18 years or older with laboratory-confirmed COVID-19 admitted to the Annunziata Hospital in Cosenza, Italy, through March 7, 2020, who received at least one dose of tocilizumab 162 mg subcutaneously for the treatment of COVID-19-related CRS in addition to standard care were included in this retrospective observational study. The primary observation was the incidence of grade 4 CRS after tocilizumab treatment. Chest computed tomography (CT) scans were evaluated to investigate lung manifestations.
FINDINGS
RESULTS
Twelve patients were included; all had fever, cough, and fatigue at presentation, and all had at least one comorbidity (hypertension, six patients; diabetes, five patients; chronic obstructive lung disease, four patients). Seven patients received high-flow nasal cannula oxygen therapy and five received non-invasive mechanical ventilation for lung complications of COVID-19. No incidence of grade 4 CRS was observed within 1 week of tocilizumab administration in all 12 patients (100%) and within 2 days of tocilizumab administration in 5 patients (42%). The predominant pattern on chest CT scans at presentation was ground-glass opacity, air bronchograms, smooth or irregular interlobular or septal thickening, and thickening of the adjacent pleura. Follow-up CT scans 7 to 10 days after tocilizumab treatment showed improvement of lung manifestations in all patients. No adverse events or new safety concerns attributable to tocilizumab were reported.
INTERPRETATION
CONCLUSIONS
Tocilizumab administered subcutaneously to patients with COVID-19 and CRS is a promising treatment for reduction in disease activity and improvement in lung function. The effect of tocilizumab should be confirmed in a randomised controlled trial.
Identifiants
pubmed: 32766535
doi: 10.1016/j.eclinm.2020.100410
pii: S2589-5370(20)30154-1
pii: 100410
pmc: PMC7329292
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100410Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
J Clin Pharmacol. 2014 Jan;54(1):109-19
pubmed: 24115082
Ann Rheum Dis. 2014 Jan;73(1):69-74
pubmed: 23904473
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Ann Oncol. 2020 Jul;31(7):961-964
pubmed: 32247642
Nat Med. 2006 Oct;12(10):1203-7
pubmed: 16964257
Cancer Discov. 2016 Jun;6(6):664-79
pubmed: 27076371
Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32
pubmed: 22390970
Blood Adv. 2020 Apr 14;4(7):1307-1310
pubmed: 32243501
Int J Clin Pharmacol Ther. 2013 Jun;51(6):443-55
pubmed: 23547848
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Ann Rheum Dis. 2016 Jan;75(1):68-74
pubmed: 26056119
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Int J Clin Pharmacol Ther. 2013 Aug;51(8):620-30
pubmed: 23782588
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
Rheumatol Ther. 2018 Jun;5(1):21-42
pubmed: 29502236
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Chin Med J (Engl). 2020 May 5;133(9):1015-1024
pubmed: 32004165
Eur J Clin Invest. 2017 Oct;47(10):736-745
pubmed: 28796316
Emerg Med Pract. 2020 Apr 16;22(5 Suppl):CD1-CD2
pubmed: 32297727
Diagn Interv Imaging. 2020 May;101(5):323-324
pubmed: 32278585
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Br J Haematol. 2018 Nov;183(3):364-374
pubmed: 30407609
Rheumatology (Oxford). 2017 Apr 1;56(4):541-549
pubmed: 28013198
Am J Hematol. 2020 Jul;95(7):876-878
pubmed: 32282956
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Eur Radiol. 2020 Jun;30(6):3306-3309
pubmed: 32055945
Ann Rheum Dis. 2018 Sep;77(9):1276-1282
pubmed: 29730637